Wanjin Hong

Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy biospace.com/business/novar…

Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill biospace.com/business/makar…

Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4 biospace.com/business/lilly…

Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’ biospace.com/drug-developme…

BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline biospace.com/business/biont…

Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline biospace.com/drug-developme…

Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III biospace.com/drug-developme…

AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront biospace.com/deals/astrazen…

J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror' biospace.com/business/j-j-a…

Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch biospace.com/business/novo-…

FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report biospace.com/fda/fda-delays…

AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market biospace.com/deals/abbvie-b…

J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark biospace.com/drug-developme…

Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones biospace.com/business/lilly…

Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race biospace.com/fda/novos-wego…

Trump Administration Reaches Pricing Agreements with 9 More Drugmakers biospace.com/policy/trump-a…

BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour biospace.com/deals/bms-forg…

Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech biospace.com/business/zeala…

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges biospace.com/drug-developme…